Tag: Ian M. Waxman

BMS gets Opdivo EC approval for second-line treatment of ESCC

Opdivo EC approval : Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for its immunotherapy Opdivo (nivolumab) as a second-line treatment ... Read More